ACELRX PHARMACEUTICALS, INC. (NASDAQ:ACRX) Files An 8-K Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure.

AcelRx Pharmaceuticals, Inc. (the Company or AcelRx) will host an
Analyst Investor Event on Thursday, December 1, 2016 in New York
from 8:00am 10:30am ET to discuss the Companys late-stage product
candidate, ARX-04. The presentation, which includes a slide
setting forth certain cautionary language intended to qualify the
forward-looking statements included in the presentation, is
furnished as Exhibit 99.1 to this Current Report and is
incorporated herein by reference. The presentation will also be
made available in the Investor Relations section of AcelRx
Pharmaceuticals, Inc.s website, located at www.acelrx.com.

The information contained in this Item 7.01 and in the
accompanying Exhibit 99.1 to this Current Report shall be deemed
to be furnished and shall not be deemed to be filed for purposes
of Section 18 of the Exchange Act, or otherwise subject to the
liabilities of that Section or Sections 11 and 12(a)(2) of the
Securities Act. The information contained in this Item 7.01 and
in the accompanying Exhibit 99.1 to this Current Report shall not
be incorporated by reference into any filing with the U.S.
Securities and Exchange Commission under the Securities Act or
the Exchange Act made by the Company, whether made before or
after the date hereof, regardless of any general incorporation
language in such filing.

(d) Exhibits.

About ACELRX PHARMACEUTICALS, INC. (NASDAQ:ACRX)

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.

ACELRX PHARMACEUTICALS, INC. (NASDAQ:ACRX) Recent Trading Information

ACELRX PHARMACEUTICALS, INC. (NASDAQ:ACRX) closed its last trading session 00.00 at 3.10 with 199,255 shares trading hands.